We are live on ! Find out more
MLTX icon

MoonLake Immunotherapeutics
MLTX

83 hedge funds and large institutions have $2.86B invested in MoonLake Immunotherapeutics in 2023 Q2 according to their latest regulatory filings, with 47 funds opening new positions, 25 increasing their positions, 8 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

571% more first-time investments, than exits

New positions opened: 47 | Existing positions closed: 7

400% more funds holding in top 10

Funds holding in top 10: 2 → 10 (+8)

239% more capital invested

Capital invested by funds: $843M → $2.86B (+$2.02B)

213% more repeat investments, than reductions

Existing positions increased: 25 | Existing positions reduced: 8

93% more funds holding

Funds holding: 43 → 83 (+40)

27.75% more ownership

Funds ownership: 100.69% → 128.44% (+28%)

Holders
83
Holders Change
+40
Holders Change %
+93.02%
% of All Funds
1.3%
Holding in Top 10
10
Holding in Top 10 Change
+8
Holding in Top 10 Change %
+400%
% of All Funds
0.16%
New
47
Increased
25
Reduced
8
Closed
7
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
+$78.1M
2
ACA
Avoro Capital Advisors
New York
+$46.4M
3
CAM
Cormorant Asset Management
Massachusetts
+$33.6M
4
T. Rowe Price Investment Management
T. Rowe Price Investment Management
Maryland
+$30.9M
5
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$29.9M

Top Sellers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
-$24.3M
2
Adage Capital Partners
Adage Capital Partners
Massachusetts
-$7.98M
3
GPP
Great Point Partners
Connecticut
-$5.95M
4
Axa
Axa
France
-$3.94M
5
Balyasny Asset Management
Balyasny Asset Management
Illinois
-$3.45M
Name Holding Trade Value Shares
Change 		Change in
Stake
JP Morgan Chase
26
JP Morgan Chase
New York
$15.2M -$136K -5,044 -2%
MB
27
MPM BioImpact
Massachusetts
$15.1M +$7.94M +295,111 New
Invesco
28
Invesco
Georgia
$13.4M +$2.29M +85,090 +48%
SCM
29
Silverarc Capital Management
Massachusetts
$10.2M +$2.54M +94,250 +89%
Franklin Resources
30
Franklin Resources
California
$10.2M +$5.38M +200,000 New
Lord, Abbett & Co
31
Lord, Abbett & Co
New Jersey
$9.93M +$5.24M +194,703 New
Millennium Management
32
Millennium Management
New York
$9.81M +$4.23M +157,333 +449%
SAM
33
Sectoral Asset Management
Quebec, Canada
$9.41M +$4.97M +184,590 New
Morgan Stanley
34
Morgan Stanley
New York
$8.13M +$3.41M +126,906 +390%
Axa
35
Axa
France
$7.9M -$3.94M -146,422 -49%
N
36
Nuveen
North Carolina
$7.14M +$3.77M +140,000 New
HS
37
HighVista Strategies
Massachusetts
$6.62M +$202K +7,521 +6%
SSA
38
Schonfeld Strategic Advisors
New York
$6.02M +$2.17M +80,760 +217%
O
39
OrbiMed
New York
$5.97M +$3.15M +117,000 New
DTC
40
Deep Track Capital
Connecticut
$5.53M +$2.92M +108,450 New
TD Asset Management
41
TD Asset Management
Ontario, Canada
$5.08M +$870K +32,328 +48%
JFG
42
Jefferies Financial Group
New York
$4.78M +$648K +24,076 +35%
ABG
43
Ally Bridge Group
New York
$4.66M +$499K +18,563 +25%
Goldman Sachs
44
Goldman Sachs
New York
$4.56M +$2.41M +89,501 New
ACM
45
Altium Capital Management
New York
$4.49M +$2.37M +88,000 New
PHP
46
Parkman Healthcare Partners
Connecticut
$4.08M +$2.15M +80,000 New
GIM
47
Granahan Investment Management
Massachusetts
$3.67M -$45.8K -1,703 -2%
Balyasny Asset Management
48
Balyasny Asset Management
Illinois
$3.54M -$3.45M -128,366 -65%
Manulife (Manufacturers Life Insurance)
49
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$3.2M +$382K +14,187 +29%
Hudson Bay Capital Management
50
Hudson Bay Capital Management
Connecticut
$3.06M +$1.61M +60,000 New
1
2
3 4

MLTX Hedge Fund Activity: Q2 2023 in Review

83 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in MoonLake Immunotherapeutics (MLTX) for Q2 2023, worth a combined $2.86B — up 239% from $843M a quarter earlier.

Buyers outnumbered sellers: 47 funds opened new MLTX positions and 7 closed out — a net gain of 40 holders — while 25 added to existing stakes and 8 trimmed.

The largest buyer was Fidelity Investments, adding an estimated $78.1M. The largest seller was Citadel Advisors, cutting an estimated $24.3M.

  • 83 institutional investors held MoonLake Immunotherapeutics (MLTX) as of Q2 2023, up from 43 in Q1 2023.
  • Funds reported $2.86B of MoonLake Immunotherapeutics stock for Q2 2023, up 239% quarter-over-quarter.
  • 47 funds opened new MoonLake Immunotherapeutics positions in Q2 2023 and 7 closed out, a net change of +40 holders.
  • The largest MoonLake Immunotherapeutics buyer in Q2 2023 was Fidelity Investments, an estimated $78.1M added.
  • The largest MoonLake Immunotherapeutics seller in Q2 2023 was Citadel Advisors, an estimated $24.3M sold.

Based on aggregated 13F filings for Q2 2023.